{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:08:53Z","timestamp":1794643733024,"version":"4.9.1"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vascular endothelial growth factor receptor 3 (VEGFR-3) binds VEGF-C and VEGF-D and is essential for the development of the lymphatic vasculature. Experimental tumors that overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and show enhanced metastasis to regional lymph nodes and beyond, whereas a soluble form of VEGFR-3 that blocks receptor signaling inhibits these changes and metastasis. Because VEGFR-3 is also essential for the early blood vessel development in embryos and is up-regulated in tumor angiogenesis, we wanted to determine if an antibody targeting the receptor that interferes with VEGFR-3 ligand binding can inhibit primary tumor growth. Our results show that antibody interference with VEGFR-3 function can inhibit the growth of several human tumor xenografts in immunocompromised mice. Immunohistochemical analysis showed that the blood vessel density of anti-VEGFR-3\u2013treated tumors was significantly decreased and hypoxic and necrotic tumor tissue was increased when compared with tumors treated with control antibody, indicating that blocking of the VEGFR-3 pathway inhibits angiogenesis in these tumors. As expected, the anti-VEGFR-3\u2013treated tumors also lacked lymphatic vessels. These results suggest that the VEGFR-3 pathway contributes to tumor angiogenesis and that effective inhibition of tumor progression may require the inhibition of multiple angiogenic targets. [Cancer Res 2007;67(2):593\u20139]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3567","type":"journal-article","created":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T11:53:23Z","timestamp":1169121203000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth"],"prefix":"10.1158","volume":"67","author":[{"given":"Pirjo","family":"Laakkonen","sequence":"first","affiliation":[{"name":"1Molecular\/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Waltari","sequence":"additional","affiliation":[{"name":"1Molecular\/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Holopainen","sequence":"additional","affiliation":[{"name":"1Molecular\/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"3Division of Molecular Carcinogenesis, Center for Nuerological Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronislaw","family":"Pytowski","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Steiner","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hicklin","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Persaud","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Tonra","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Witte","sequence":"additional","affiliation":[{"name":"2ImClone Systems, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Alitalo","sequence":"additional","affiliation":[{"name":"1Molecular\/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,1,18]]},"reference":[{"key":"2022061623360303500_B1","doi-asserted-by":"crossref","unstructured":"Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science\u20081998; 282: 946\u20139.","DOI":"10.1126\/science.282.5390.946"},{"key":"2022061623360303500_B2","doi-asserted-by":"crossref","unstructured":"Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A\u20081995; 92: 3566\u201370.","DOI":"10.1073\/pnas.92.8.3566"},{"key":"2022061623360303500_B3","doi-asserted-by":"crossref","unstructured":"Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J\u20082000; 14: 2087\u201396.","DOI":"10.1096\/fj.99-1049com"},{"key":"2022061623360303500_B4","doi-asserted-by":"crossref","unstructured":"Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med\u20082001; 7: 199\u2013205.","DOI":"10.1038\/84651"},{"key":"2022061623360303500_B5","doi-asserted-by":"crossref","unstructured":"Covassin LD, Villefranc JA, Kacergis MC, Weinstein BM, Lawson ND. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci U S A\u20082006; 103: 6554\u20139.","DOI":"10.1073\/pnas.0506886103"},{"key":"2022061623360303500_B6","doi-asserted-by":"crossref","unstructured":"Ober EA, Olofsson B, Makinen T, et al. Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep\u20082004; 5: 78\u201384.","DOI":"10.1038\/sj.embor.7400047"},{"key":"2022061623360303500_B7","doi-asserted-by":"crossref","unstructured":"Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med\u20082001; 7: 192\u20138.","DOI":"10.1038\/84643"},{"key":"2022061623360303500_B8","doi-asserted-by":"crossref","unstructured":"Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med\u20082001; 7: 186\u201391.","DOI":"10.1038\/84635"},{"key":"2022061623360303500_B9","unstructured":"Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res\u20082001; 61: 1786\u201390."},{"key":"2022061623360303500_B10","doi-asserted-by":"crossref","unstructured":"Mattila MM, Ruohola JK, Karpanen T, et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer\u20082002; 98: 946\u201351.","DOI":"10.1002\/ijc.10283"},{"key":"2022061623360303500_B11","doi-asserted-by":"crossref","unstructured":"Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J\u20082001; 20: 672\u201382.","DOI":"10.1093\/emboj\/20.4.672"},{"key":"2022061623360303500_B12","doi-asserted-by":"crossref","unstructured":"He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst\u20082002; 94: 819\u201325.","DOI":"10.1093\/jnci\/94.11.819"},{"key":"2022061623360303500_B13","unstructured":"Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res\u20082003; 63: 713\u201322."},{"key":"2022061623360303500_B14","doi-asserted-by":"crossref","unstructured":"Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res\u20082005; 65: 6901\u20139.","DOI":"10.1158\/0008-5472.CAN-05-0408"},{"key":"2022061623360303500_B15","doi-asserted-by":"crossref","unstructured":"Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science\u20082002; 296: 1883\u20136.","DOI":"10.1126\/science.1071420"},{"key":"2022061623360303500_B16","doi-asserted-by":"crossref","unstructured":"He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res\u20082005; 65: 4739\u201346.","DOI":"10.1158\/0008-5472.CAN-04-4576"},{"key":"2022061623360303500_B17","doi-asserted-by":"crossref","unstructured":"Dixelius J, Makinen T, Wirzenius M, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem\u20082003; 278: 40973\u20139.","DOI":"10.1074\/jbc.M304499200"},{"key":"2022061623360303500_B18","doi-asserted-by":"crossref","unstructured":"Nilsson I, Rolny C, Wu Y, et al. Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. FASEB J\u20082004; 18: 1507\u201315.","DOI":"10.1096\/fj.03-1276com"},{"key":"2022061623360303500_B19","doi-asserted-by":"crossref","unstructured":"Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol\u20081999; 154: 1381\u201390.","DOI":"10.1016\/S0002-9440(10)65392-8"},{"key":"2022061623360303500_B20","doi-asserted-by":"crossref","unstructured":"Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood\u20082000; 96: 546\u201353.","DOI":"10.1182\/blood.V96.2.546.014k12_546_553"},{"key":"2022061623360303500_B21","doi-asserted-by":"crossref","unstructured":"Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst\u20082005; 97: 14\u201321.","DOI":"10.1093\/jnci\/dji003"},{"key":"2022061623360303500_B22","unstructured":"Kozaki K, Miyaishi O, Tsukamoto T, et al. Establishment and characterization of a human lung cancer cell line NCI-H460-35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res\u20082000; 60: 2535\u201340."},{"key":"2022061623360303500_B23","unstructured":"Jussila L, Valtola R, Partanen TA, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res\u20081998; 58: 1599\u2013604."},{"key":"2022061623360303500_B24","unstructured":"Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res\u20082003; 63: 4009\u201316."},{"key":"2022061623360303500_B25","doi-asserted-by":"crossref","unstructured":"Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med\u20082002; 8: 751\u20135.","DOI":"10.1038\/nm720"},{"key":"2022061623360303500_B26","doi-asserted-by":"crossref","unstructured":"Karpanen T, Wirzenius M, Makinen T, et al. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol\u20082006; 169: 708\u201318.","DOI":"10.2353\/ajpath.2006.051200"},{"key":"2022061623360303500_B27","doi-asserted-by":"crossref","unstructured":"Garces CA, Kurenova EV, Golubovskaya VM, Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res\u20082006; 66: 1446\u201354.","DOI":"10.1158\/0008-5472.CAN-05-1661"},{"key":"2022061623360303500_B28","doi-asserted-by":"crossref","unstructured":"Longatto Filho A, Martins A, Costa SM, Schmitt FC. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract\u20082005; 201: 93\u20139.","DOI":"10.1016\/j.prp.2004.11.008"},{"key":"2022061623360303500_B29","doi-asserted-by":"crossref","unstructured":"Su JL, Yang PC, Shih JY, et al. The VEGF-C\/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell\u20082006; 9: 209\u201323.","DOI":"10.1016\/j.ccr.2006.02.018"},{"key":"2022061623360303500_B30","doi-asserted-by":"crossref","unstructured":"Yang J, Wu HF, Qian LX, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl\u20082006; 8: 169\u201375.","DOI":"10.1111\/j.1745-7262.2006.00120.x"},{"key":"2022061623360303500_B31","unstructured":"Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res\u20081992; 52: 5738\u201343."},{"key":"2022061623360303500_B32","doi-asserted-by":"crossref","unstructured":"Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol\u20081998; 153: 395\u2013403.","DOI":"10.1016\/S0002-9440(10)65583-6"},{"key":"2022061623360303500_B33","doi-asserted-by":"crossref","unstructured":"Persaud K, Tille JC, Liu M, et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci\u20082004; 117: 2745\u201356.","DOI":"10.1242\/jcs.01138"},{"key":"2022061623360303500_B34","doi-asserted-by":"crossref","unstructured":"Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer\u20082002; 2: 573\u201383.","DOI":"10.1038\/nrc863"},{"key":"2022061623360303500_B35","doi-asserted-by":"crossref","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol\u20082003; 21: 60\u20135.","DOI":"10.1200\/JCO.2003.10.066"},{"key":"2022061623360303500_B36","doi-asserted-by":"crossref","unstructured":"Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol\u20082002; 161: 947\u201356.","DOI":"10.1016\/S0002-9440(10)64255-1"},{"key":"2022061623360303500_B37","doi-asserted-by":"crossref","unstructured":"Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res\u20082006; 66: 2650\u20137.","DOI":"10.1158\/0008-5472.CAN-05-1843"},{"key":"2022061623360303500_B38","doi-asserted-by":"crossref","unstructured":"Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer\u20082002; 2: 727\u201339.","DOI":"10.1038\/nrc905"},{"key":"2022061623360303500_B39","doi-asserted-by":"crossref","unstructured":"Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature\u20082005; 438: 946\u201353.","DOI":"10.1038\/nature04480"},{"key":"2022061623360303500_B40","doi-asserted-by":"crossref","unstructured":"Samoszuk MK, Walter J, Mechetner E. Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. J Histochem Cytochem\u20082004; 52: 837\u20139.","DOI":"10.1369\/jhc.4B6248.2004"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/2\/593\/2866808\/593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/2\/593\/2866808\/593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:18:01Z","timestamp":1655425081000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/2\/593\/533532\/Vascular-Endothelial-Growth-Factor-Receptor-3-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,15]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,1,18]]},"published-print":{"date-parts":[[2007,1,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3567","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495906.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495906","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368318.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368315.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,15]]}}}